Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312147 | 0.87 | PRMT5 (0.46) | MAP3K5PRMT5WDR77ABHD6PTGDR2 | |
| SCHEMBL15355424 | 0.78 | PRMT5 (0.67) | PRMT5WDR77ABHD6 | |
| SCHEMBL14868188 | 0.71 | ESR2 (0.50) | MAP3K5PRMT5WDR77ABHD6 | |
| SCHEMBL1201971 | 0.68 | PRMT5 (0.48) | MAP3K5PRMT5WDR77ABHD6PTGDR2 | |
| SCHEMBL10197664 | 0.68 | CARM1 (0.53) | MAP3K5CARM1ABHD6 | |
| SCHEMBL28486528 | 0.68 | RAB9A (0.44) | MAP3K5PRMT5WDR77PTGDR2HRH1 | |
| SCHEMBL15504678 | 0.67 | ALDH1A1 (0.43) | CARM1ABHD6 | |
| SCHEMBL1857142 | 0.67 | UCHL1 (0.53) | ABHD6 | |
| SCHEMBL30647075 | 0.67 | UCHL1 (0.53) | ABHD6 | |
| SCHEMBL30404761 | 0.67 | TMEM97 (0.47) | MAP3K5PRMT5WDR77ABHD6ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | MAP3K5 4519/4885PRMT5 2013/4885WDR77 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.